Article

Eye drop offers action at surface, cellular levels

A new generation of dry eye therapy is artificial tears offering both lubricating and osmoprotective components that protect the eye at the surface and the cellular level.

Key Points

"One of the unique aspects of this tear compared with some of the others is that it provides lubrication to the ocular surface, but it also helps with osmoprotection, keeping the epithelial cells healthy and functioning," said David R. Hardten, MD, founding partner and director of external disease, Minnesota Eye Consultants, Minneapolis. Dr. Hardten, who also is an adjunct associate professor at the University of Minnesota, has conducted studies of the drops when used in conjunction with topical cyclosporine A (Restasis, Allergan).

Some drops treat dry eye by providing more water to dilute the build-up of salts, but relief from symptoms is only momentary, Dr. Wilson said. "The solutes in [this product] keep liquid within the epithelial cells and provide a relatively longer-term relief from the dry eye, which is exactly what was observed when [the manufacturer] did the initial studies comparing [these eye drops] to several other available artificial tears."

"This is a new treatment strategy for dry eye," said William Trattler, MD, Center for Excellence in Eye Care, Miami. "It's a next-generation artificial tear for all forms of dry eye. Some of my patients who have tried it have noticed a real difference. They say it's very comfortable and that it works really well for them."

He said he has been recommending it as the first-line dry eye treatment for new patients as well as suggesting it to established patients who are searching for a more effective artificial tear, those who need to use a tear in conjunction with topical cyclosporine, and patients who have had surgery.

"One of the nice things about [the product] is that it fits in for a broad spectrum of dry eye patients," Dr. Hardten said. "For the intermittent user of artificial tears and even up to those with moderate or severe dry eye, it's a very comfortable drop. When you put it in, it doesn't blur for very long and it doesn't sting."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.